-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Basic condition of the patient
Gender: Male
Age: 59
Basic situation: In December 2015, the patient underwent total thyroidectomy of the left and right lobes, followed by radioactive iodine therapy
.
During the follow-up of the disease, it was found that the patient had progressed to the disease and had multiple metastases
in bone, lung and lymph nodes.
Personal history: no history of smoking, alcohol consumption, allergies, or substance abuse
The patient's previous treatment history
On 8 December 2015, the patient underwent total left and right thyroidectomy
Surgical treatment: total left and right lobectomy of the thyroid gland
Postoperative pathological results: follicular carcinoma of the thyroid gland (FTC), differentiation grade unknown
From 12 January 2016 to 16 May 2016, the patient was treated with radioactive iodine
The patient was treated with radioactive iodine and subsequent systemic imaging showed no iodine uptake lesions
Donafenib treatment undergoes
Baseline: height 160cm, weight 67.
2kg, BMI 26.
25kg/m², Eastern Cancer Collaborative Group physical status score (ECOG PS) 0, no previous systemic therapy;Tumor baseline: T3N1M1, target lesion 15.
3mm, multiple metastases in bone, lung and lymph nodes;Laboratory baseline: thyroid-stimulating hormone (TSH) 0.
447 mIU/L (local laboratory); Thyroglobulin (Tg) 1446 ng/mL, thyroglobulin antibody (TgAb) 12.
61 IU/mL (central laboratory).On June 21, 2019, the patient was enrolled in the DIRECTION study and started oral multikinase inhibitor donafenib 300 mg twice
daily.At week 8 of enrollment, the patient achieved partial remission (PR);
The patient was assessed by the Center for Independent Review (IRC) as having a progression-free survival (PFS) of 18.
3 months, with the best overall response to PR.
As of February 28, 2021 (the deadline for study data analysis), patients are still on
medication.
Laboratory evaluation
Tg levels and TSH levels changed from baseline to day 616 of treatment
Imaging tests
Target lesions and overall efficacy changed from baseline to week 88 of treatment
Fig.
1.
Imaging changes of target lesion 001 in patients during donafenib treatment
Figure 2.
Changes in target lesions evaluated by central imaging during donafenib treatment
Table 1.
Changes in target lesions in patients during donafenib treatment
Donafenib treatment-related adverse reactions (TRAE) occur
Case summary
This case is FTC, and after total thyroidectomy of the left and right lobes, he was treated with radioactive iodine, and subsequent whole-body imaging did not show iodine uptake lesions
.
On June 21, 2019, after multiple evaluations, the patient met the inclusion criteria for the DIRECTION study and was enrolled in the clinical study
.
At the 8th week of treatment, the patient's imaging results showed that the disease had reached PR.
As of the time of data analysis, the patient's tumor had been maintained in PR status after the investigator's assessment, and the investigator's PFS was 20.
24 months
.
During the treatment period, no grade > 3 adverse events occurred, and other grade 1 and 2 adverse events were alleviated after symptomatic treatment, indicating that the safety of donafenib is controllable
.
Expert reviews
Professor Ma Qingjie
Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University
FTC is a malignancy of thyroid follicular cell origin with an incidence of approximately 6% to 10%, is more aggressive than papillary thyroid carcinoma (PTC), and is prone to distant metastasis¹
.
According to statistics, about 25% of FTC patients will have distant metastases, and the common distant metastases are lung, bone, liver, etc.
¹
.
After 4 months of radioactive iodine treatment, the whole body imaging of the patient in this case did not show iodine uptake of the lesion, indicating that the disease developed to iodine refractory
.
Although differentiated thyroid cancer (DTC, including FTC and PTC) has a better overall prognosis and lower mortality, the survival of patients with RAIR-DTC is significantly shorter, with an average survival of only 3-5 years and a 10-year survival rate of about 10%²
.
In addition, the patient has poor prognostic factors
such as bone, lung, and lymph node metastases.
Although the patient had a variety of adverse prognostic factors, the patient quickly reached PR status after 8 weeks of donafenib monotherapy and had an IRC-assessed PFS of 18.
3 months
.
The good benefit for this patient is a "microcosm" of the success of the DIRECTION study, a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety
of the deuterated drug donafenib in Chinese patients with RAIR-DTC 。 The results of the study showed that donafenib significantly prolonged mPFS in patients with RAIR-DTC (IRC assessment: 12.
9 versus 6.
4 months, HR=0.
39, p<0.
0001), and subgroup analysis showed that donafenib was able to prolong mPFS for 10.
9 months in patients with RAIR-DTC who were not treated with TKI (18.
3 vs 7.
4 months, HR=0.
45, 95% CI 0.
27-0.
73), For patients with RAIR-DTC who had previously received TKI, the trend of benefit was more pronounced in the donafenib group (11.
0 vs 3.
7 months, HR = 0.
227, 95% CI 0.
085 to 0.
609)³<b11>.
In terms of compliance and safety, the average daily dose of donafenib is 522mg/day, treatment-related adverse events (TRAEs) are mostly grade 1-2, and overall compliance is good and safety is controllable
.
Thanks to the good results achieved by donafenib in the DIRECTION study, China's National Medical Products Administration (NMPA) approved donafenib for locally advanced/metastatic RAIR-DTC patients, which is expected to become a better choice
for the treatment of RAIR-DTC patients.
References
1.
Guidelines for the diagnosis and treatment of thyroid cancer 2022 edition2.
Cong Hui,Liang Jun,Lin Yansong.
Diagnosis and targeted therapy of iodine-refractory differentiated thyroid cancer[J].
International Journal of Nuclear Medicine of Radiation Medicine,2015,39(01):25-31.
)3.
Y.
Lin, H.
Yang, F.
Shi, et al.
Donafenib in Locally Advanced/Metastatic, Radioactive Iodine-Refractory, Differentiated Thyroid Cancer: A Randomized, Double-blind, Placebo-controlled, Multi-Center Phase III Clinical Trial (DIRECTION).
ESMO Abstract 3099.
Typesetting: Youshi
Execution: Small garden
This platform aims to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with it
as soon as possible.
